Sun Beicheng, Chen Meizhen, Hawks Christina, Hornsby Peter J, Wang Xuehao
Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.
Mol Carcinog. 2006 Apr;45(4):213-9. doi: 10.1002/mc.20137.
A model of neoplastic transformation by the combination of SV40 large T antigen (LT), SV40 small T antigen (ST), oncogenic Ras, and human telomerase reverse trasncriptase subunit (hTERT) has become established and replicated in primary human fibroblasts, however, there is no report on human hepatocytes. Here we use cell transplantation model, and show that transplantation of human hepatocytes of HL-7702 and HL-7703 expressing Ha-RasV12 and SV40 LT into subrenal capsule of immunodeficient mice results in fully malignant tumors, in contrast to conventional subcutaneous injections where tumors fail to develop. In GM-847 cell study, we have found that hTERT is not required for tumorigenic growth in subrenal capsule transplantation, however, it is required in subcutaneous injection assay. These results demonstrate that Human hepatocytes can be transformed under kidney capsule by coexpressing SV40 LT and Ha-RasV12, neither hTERT nor protein phosphatase 2A (PP2A) inhibition are required for malignant transformation, a gene which increases cell survival in the subcutaneous injection model is not required for tumorigenic growth in subrenal capsule.
通过SV40大T抗原(LT)、SV40小T抗原(ST)、致癌性Ras和人类端粒酶逆转录酶亚基(hTERT)组合实现肿瘤转化的模型已在原代人成纤维细胞中建立并得到复制,然而,尚无关于人肝细胞的报道。在此,我们使用细胞移植模型,结果表明,将表达Ha-RasV12和SV40 LT的HL-7702和HL-7703人肝细胞移植到免疫缺陷小鼠的肾被膜下会导致完全恶性肿瘤的形成,这与传统皮下注射未能形成肿瘤形成对比。在GM-847细胞研究中,我们发现hTERT在肾被膜下移植的致瘤生长中并非必需,但在皮下注射试验中是必需的。这些结果表明,通过共表达SV40 LT和Ha-RasV12,人肝细胞可在肾被膜下发生转化,恶性转化既不需要hTERT也不需要抑制蛋白磷酸酶2A(PP2A),皮下注射模型中增加细胞存活的一个基因在肾被膜下致瘤生长中并非必需。